Russell Investments Group
RARE icon

Russell Investments Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Russell Investments Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2M Buy
784,099
+381,140
+95% +$9.47M 0.02% 632
2026
Q1 		$8.44M Sell
402,959
-437,861
-52% -$9.86M 0.01% 1042
2025
Q4 		$19.3M Buy
840,820
+369
+0% +$12.1K 0.02% 645
2025
Q3 		$25.3M Buy
840,451
+720,256
+599% +$21.6M 0.03% 536
2025
Q2 		$4.37M Buy
120,195
+16,373
+16% +$590K 0.01% 1299
2025
Q1 		$3.76M Buy
103,822
+34,635
+50% +$1.44M 0.01% 1323
2024
Q4 		$2.91M Sell
69,187
-19,424
-22% -$964K ﹤0.01% 1465
2024
Q3 		$4.92M Sell
88,611
-67,442
-43% -$3.44M 0.01% 1194
2024
Q2 		$6.41M Sell
156,053
-7,088
-4% -$303K 0.01% 1031
2024
Q1 		$7.62M Sell
163,141
-37,474
-19% -$1.77M 0.01% 962
2023
Q4 		$9.59M Buy
200,615
+16,728
+9% +$648K 0.02% 808
2023
Q3 		$6.56M Buy
183,887
+13,750
+8% +$545K 0.01% 952
2023
Q2 		$7.85M Sell
170,137
-12,100
-7% -$561K 0.02% 891
2023
Q1 		$7.31M Buy
182,237
+72,595
+66% +$3.12M 0.01% 916
2022
Q4 		$5.08M Buy
109,642
+16,267
+17% +$640K 0.01% 1090
2022
Q3 		$3.86M Buy
+93,375
New +$4.8M 0.01% 1188
2022
Q2 		– Sell
-3,345
Closed -$242K – 2955
2022
Q1 		$242K Buy
+3,345
New +$233K ﹤0.01% 2425
2021
Q4 		– Sell
-2,502
Closed -$225K – 3087
2021
Q3 		$225K Sell
2,502
-16,106
-87% -$1.46M ﹤0.01% 2744
2021
Q2 		$1.77M Sell
18,608
-13,446
-42% -$1.4M ﹤0.01% 1984
2021
Q1 		$3.65M Sell
32,054
-7,466
-19% -$1.02M 0.01% 1529
2020
Q4 		$5.47M Sell
39,520
-1,165
-3% -$138K 0.01% 1193
2020
Q3 		$3.34M Buy
40,685
+6,791
+20% +$563K 0.01% 1373
2020
Q2 		$2.65M Sell
33,894
-14,593
-30% -$966K 0.01% 1474
2020
Q1 		$2.15M Sell
48,487
-13,543
-22% -$703K 0.01% 1428
2019
Q4 		$2.65M Buy
62,030
+22,025
+55% +$909K ﹤0.01% 1573
2019
Q3 		$1.71M Buy
40,005
+332
+0.8% +$18K ﹤0.01% 1762
2019
Q2 		$2.52M Buy
39,673
+6,871
+21% +$437K ﹤0.01% 1562
2019
Q1 		$2.27M Buy
32,802
+5,475
+20% +$313K ﹤0.01% 1648
2018
Q4 		$1.19M Sell
27,327
-45,486
-62% -$2.49M ﹤0.01% 1863
2018
Q3 		$5.57M Buy
72,813
+45,097
+163% +$3.67M 0.01% 1244
2018
Q2 		$2.13M Sell
27,716
-576
-2% -$37.2K ﹤0.01% 1726
2018
Q1 		$1.44M Buy
28,292
+3,170
+13% +$160K ﹤0.01% 2023
2017
Q4 		$1.18M Sell
25,122
-14,998
-37% -$735K ﹤0.01% 2074
2017
Q3 		$2.14M Buy
40,120
+8,936
+29% +$529K ﹤0.01% 1751
2017
Q2 		$1.94M Buy
31,184
+3,195
+11% +$192K ﹤0.01% 1758
2017
Q1 		$1.9M Buy
27,989
+14,780
+112% +$1.13M ﹤0.01% 1775
2016
Q4 		$927K Buy
+13,209
New +$937K ﹤0.01% 2210

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Russell Investments Group's RARE Position: Q2 2026 in Review

Russell Investments Group increased its Ultragenyx Pharmaceutical (RARE) stake by 95% in Q2 2026, buying an estimated $9.47M and bringing the position to 784,099 shares worth $26.2M. The position accounts for 0.02% of the portfolio, ranked #632.

Russell Investments Group first reported a position in RARE in Q4 2016 and has held it in 37 quarters since. 99 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Russell Investments Group held 784,099 shares of Ultragenyx Pharmaceutical worth $26.2M as of Q2 2026.
  • Russell Investments Group bought 381,140 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $9.47M.
  • Ultragenyx Pharmaceutical made up 0.02% of Russell Investments Group's portfolio in Q2 2026, its #632 holding.
  • Russell Investments Group first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and has held it in 37 quarters since.
  • 99 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.